FORM sacompleted form, insurance information, and dinical documentation to: 80 - 209-47456 Patient Name:	EFGARTIGIMOD ALFA-FCAB (VYVGART®) AND								
Patient Name: Date of Birth:	EFGARTIGIMOD ALFA AND HYALURONIDASE-QVFC (VYVGART® HYTRULO) PRESCRIBER ORDER For completed form, insurance information, and clinical documentation to: 850-290-7456								
Phone: Height: Inches Cm Weight: Ibs kg	FURIVI								
Phone: Height: Inches Cm Weight: Ibs kg	②								
Primary Diagnosis Description: Generalized myasthenia gravis (gMG) Prescription Prescriber Presc	option care health			Height:	☐ inches ☐	cm	Weight:	☐ lbs ☐ kg	
VYVGART* (efgartigimod alfa-fcab) 400mg in 20mL			al Information						
DVVVGART* (efgartigimod alfa-fcab) 400mg in 20mL Infuse 10 mg/kg V over one (1) hour every week x 4 weeks for 1 treatment cycle Max 1200mg dose for patients >120kg	, , , , , ,								
Additional Vyvgart orders: Ancillary Orders	 VYVGART® (efgartigimod alfa-fcab) 400mg in 20mL Infuse 10 mg/kg IV over one (1) hour every week x 4 weeks for 1 treatment cycle Max 1200mg dose for patients >120kg Using a 50 mL NS IV bag, flush IV tubing with NS 10 to 20 mL after each infusion Infuse via 0.2 micron in-line filter Dispense quantity sufficient of 400mg single dose vials for each dose. Round calculated dose to nearest 20mg increment. Withdraw calculated dose from vial and discard any unused vial contents. □ VYVGART® HYTRULO (efgartigimod alfa and hyaluronidase-qvfc) 1008mg/11,200 units in 5.6mL Infuse Subcutaneously over 30-90 seconds every week x 4 weeks for 1 treatment cycle Administer using a winged 25G 12in tubing (maximum priming volume of 0.4 mL) 								
Anaphylaxis Kit Dosage: Dosage: Dosage: Diphenhydramine 25 mg (> 30 kg), 0.15 mg (15 to 30 kg), or 0.01 mg/kg (< 15 kg) SQ or IM x 1; repeat x 1 in 5 to 15 min PRN. Diphenhydramine 25 mg (> 30 kg) or 1.25 mg/kg (≤ 30 kg) IV or IM; repeat x 1 in 15 min PRN no improvement. Normal saline 500 mL (> 30 kg) or 250 mL (≤ 30 kg) IV at KVO rate PRN anaphylaxis. Patients ≤ 30 kg, infuse over 2 to 4 hours PRN headache rated > 5 on pain scale. Pre-Medication Orders Diphenhydramine 25 mg (> 30 kg) or 250 mL (≤ 30 kg) IV at KVO rate PRN anaphylaxis. Patients ≤ 30 kg, infuse over 2 to 4 hours Peripheral: No Fundamental Port: No S 2 to 3 mL pre-/post-use and 10 to 20 mL pre-/post-lab draw. Heparin (100 unit/mL) 3 to 5 mL post-use. For maintenance, heparin (100 unit/mL) 3 to 5 mL every 24 hr if accessed or weekly to monthly if not accessed. Dother: Lab Orders Lab Orders Certify that the use of the indicated treatment is medically necessary and that I will be supervising the patient's treatment. Prescriber Signature: Date: Prescriber Information Prescriber Name: Phone: Page 1									
Peripheral: NS 2 to 3 mL pre-/post-use. Implanted Port: NS 5 to 10 mL pre-/post-use and 10 to 20 mL pre-/post-lab draw. Heparin (100 unit/mL) 3 to 5 mL post-use. For maintenance, heparin (100 unit/mL) 3 to 5 mL every 24 hr if accessed or weekly to monthly if not accessed. Other:	Anaphylaxis Kit Dosage: ■ Epinephrine 0.3 mg (> 30 kg), 0.15 mg (15 to 30 kg), or 0.01 mg/kg (< 15 kg) SQ or IM x 1; repeat x 1 in 5 to 15 min PRN. ■ Diphenhydramine 25 mg (> 30 kg) or 1.25 mg/kg (≤ 30 kg) IV or IM; repeat x 1 in 15 min PRN no improvement. ■ Normal saline 500 mL (> 30 kg) or 250 mL (≤ 30 kg) IV at KVO rate PRN anaphylaxis. Patients ≤ 30 kg, infuse over 2 to 4 hours PRN headache rated > 5 on pain scale.								
□ No labs ordered at this time. □ Other: Skilled nurse to assess and administer via access device as indicated above. Nurse will provide ongoing support as needed. Refill above ancillary orders as directed x 1 year. I certify that the use of the indicated treatment is medically necessary and that I will be supervising the patient's treatment. Prescriber Signature: Date: Prescriber Information Prescriber Name: Phone: Fax:	 □ Peripheral: □ Implanted Port: NS 2 to 3 mL pre-/post-use. □ Implanted Port: NS 5 to 10 mL pre-/post-use and 10 to 20 mL pre-/post-lab draw. Heparin (100 unit/mL) 3 to 5 mL post-use. For maintenance, heparin (100 unit/mL) 3 to 5 mL every 24 hr if accessed or weekly to monthly if not accessed. 								
Skilled nurse to assess and administer via access device as indicated above. Nurse will provide ongoing support as needed. Refill above ancillary orders as directed x 1 year. I certify that the use of the indicated treatment is medically necessary and that I will be supervising the patient's treatment. Prescriber Signature:									
directed x 1 year. I certify that the use of the indicated treatment is medically necessary and that I will be supervising the patient's treatment. Prescriber Signature: Date: Prescriber Information Prescriber Name: Phone: Fax:	_								
Prescriber Signature: Date: Prescriber Information Prescriber Name: Phone: Fax:		and administer via access device as	indicated above.	Nurse will provide ongo	ing support as ne	eded. F	Refill above ancillary o	rders as	
Prescriber Information Prescriber Name: Phone: Fax:	I certify that the use of the indicated treatment is medically necessary and that I will be supervising the patient's treatment.								
Prescriber Name: Phone: Fax:						Date:			
7 TO 1000					Tua.				
City. State: Zio: Office Contact:	City, State: Zip:			Office Contact:					

CONFIDENTIAL HEALTH INFORMATION: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization or under circumstances that do not require authorization. You are obligated to maintain it in a safe, secure, and confidential manner. Re-disclosure of this information is prohibited unless permitted by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure or failure to maintain confidentiality could subject you to penalties described in federal and state laws. IMPORTANT WARNING: This message is intended for the use of the person or entity to whom it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately. Brand names are the property of their respective owners.